secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001193125-22-281247
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q3 revenue $40.5M (+18% YoY); net income $1.6M; guides FY near high end of $160-168M
--------------------------------------------------------------------------------

- Revenue $40.5M (+18% YoY); gross margin improved to 66.4% from 61.9%.
- Net income $1.6M (vs $1.4M); adjusted EBITDA $7.3M (vs $5.5M).
- FY2022 revenue guidance reaffirmed closer to high end of $160M-$168M range.
- Appointed Chris Williams as Chief Operating Officer during the quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522281247/0001193125-22-281247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522281247/d384960d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-281247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer